
Women’s health clinical trials: breaking down barriers through decentralisation
Women tend to be harder to recruit for clinical trials due to socioeconomic factors. But decentralised study designs help ease…
ByWomen tend to be harder to recruit for clinical trials due to socioeconomic factors. But decentralised study designs help ease…
ByCurrently, the UK accounts for 16% of global cell therapy manufacturing facilities, according to GlobalData’s Contract Service Provider Database.
ByThe results investigated the efficacy and safety of cabotegravir/rilpivirine, the company’s once-monthly injection for treating HIV.
ByEight months in, Nigel Hughes, Scientific Director JCI-PDR, Janssen, examines the ramifications of GDPR on the industry now the regulation…
John Shillingford, Clinical Operations Director, Orsus Medical, describes the inherent challenges facing small- to mid-sized medical device companies
Gavin Davidson, CVMD Analyst, GlobalData, examines how MDMA is used to treat patients with PTSD
Hedley Rees, Chief Disruptor, PharmaFlow, discusses the need for a rethink on supply chain processes
Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded information in clinical trials
Thank you for subscribing to Clinical Trials Arena